Kenvue (NYSE:KVUE) is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels. Its product mix spans skincare and cosmetics, toiletries and oral hygiene, baby and family care products, adhesive and wound care, and OTC analgesics and remedies. Kenvue sells finished consumer products through traditional brick‑and‑mortar retailers, pharmacies and increasingly through e‑commerce and direct‑to‑consumer channels.
Kenvue was formed as part of a corporate separation from Johnson & Johnson in 2023 and operates as an independent public company headquartered in the United States. It maintains a global presence, serving markets across North America, Europe, Asia and other regions through regional sales networks and international distribution partners. The company’s leadership team is drawn from executives with experience in consumer health and brand management; Thibaut Mongon has served as chief executive following the separation.
As a consumer health-focused business, Kenvue emphasizes brand building, research and development for consumer‑facing products, and the optimization of supply‑chain and go‑to‑market capabilities. Its strategic priorities include innovation in product formulations and packaging, expanding digital and retail distribution, and leveraging consumer insights to support growth across established and emerging markets.
